![Stephen ESMO biosimilar](/sites/default/files/styles/square_card_l/public/media/images/media-1255.jpg.webp?itok=qXzNuvb2)
Are biosimilars the key to access, in practice?
Stephen Scowcroft, our Business Development Manager, reports back from the European Society of Medical Oncology (ESMO) Congress 2018 #ESMO18.
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
Stephen Scowcroft, our Business Development Manager, reports back from the European Society of Medical Oncology (ESMO) Congress 2018 #ESMO18.
NICE recommending Kymriah for young people with B-cell acute lymphoblastic leukaemia (ALL)
Medicinal cannabis can now be prescribed for adults with chemotherapy-related nausea or vomiting, who haven't responded to licensed treatment.
Ground-breaking treatment offers new hope.
Education and Training Manager Helen Mee reflects on the first of a series of conferences for people with lymphoma
Newer antibody still not recommended in Scotland
Your insight could support a NICE assessment for brentuximab vedotin
Our response to the NICE draft decision to reject CAR-T cell technology on the NHS.
Dr Becky Salisbury, our Senior Medical Writer, blogs about one of the hot topics from the recent British Society of Haematology meeting.
Positive update about ibrutinib and relapsed chronic lymphocytic leukaemia (CLL)